Clinical Trial Update: Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age [Phase 4]

View source ↗

Summary

A Phase 4 CDC-sponsored study assessed the immunogenicity of the Measles-Rubella vaccine in infants at 6 and 9 months, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Rubella Syndrome
• Measles
• Rubella

Drugs mentioned

• Measles-Rubella Vaccine (Measles and Rubella vaccine)

Snippet

Sponsor: Centers for Disease Control and Prevention | Conditions: Measles, Rubella | Phase 4 | Status: COMPLETED | Results posted: 2025-07-16